Company intelligence / Profile preview

Theragen Bio

Ownership: Private
Development stage: Commercial

Overview

All disclosed therapeutic programs are in preclinical or discovery stages. No clinical results reported yet. The company’s main focus remains on leveraging genomics and AI to develop next-generation personalized anti-cancer drugs.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateTherapeutic vaccineBiological productSmall molecule
Industry: Biotech

Partnerships

Illumina/AWS for NGS analytics infrastructure

Beyond the preview

Go deeper on Theragen Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theragen Bio.

Explore the full profile